<DOC>
	<DOC>NCT00692614</DOC>
	<brief_summary>This study will evaluate the treatment effect of three doses of the I-vation TA implant (MK0140) in diabetic patients with clinically significant macular edema.</brief_summary>
	<brief_title>A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Patient has clinically significant macular edema as a result of their diabetes (Type I or Type 2) Patient has in the study eye, 20/40 20/160 vision Patient has Type 1 or Type 2 diabetes Patient agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control Patient has had any active ocular infection in either eye Patient has intraocular pressure &gt; 22 mmHg or a diagnosis of glaucoma Patient has cystoid macular edema in the study eye Patient has a history of elevated IOP in response to ocular steroid therapy in either eye Patient has had intraocular surgery in the study eye within 6 months prior to Visit 1 Patient has an HbAIc value &gt; 10% at Visit 1 Patient has within the last 4 months initiated intensive insulin treatment or plan to do so in the next 4 months Patient has a history of cancer within 5 years prior to signing informed consent Patient has clinicallyrelevant chronic renal failure Patient has high blood pressure Patient has coronary heart disease Patient has known allergies to steroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>